D 4418

Drug Profile

D 4418

Latest Information Update: 22 Oct 1998

Price : $50

At a glance

  • Originator Celltech Group
  • Class Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 22 Oct 1998 Discontinued-I for Asthma in United Kingdom (PO)
  • 22 May 1997 Phase-I clinical trials for Asthma in United Kingdom (PO)
  • 15 Nov 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top